The Therapeutic Goods
Administration (TGA) has approved
Breo Ellipta (fluticasone furoate/
vilanterol trifenatate) for asthma
and chronic obstructive pulmonary
disease (COPD).
Sponsors GSK Australia and
Theravance Inc said it was the
first combination of an inhaled
corticosteroid and a long-acting
beta-agonist, with two strengths
licensed for the treatment of
asthma - 100/25 mcg and 200/25
mcg - and the former for COPD.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Apr 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.